Accessibility Menu
Boundless Bio logo

Boundless Bio(NASDAQ) BOLD

Market Cap$57.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-82%
5 YearN/A
1 Year+106%
1 Month-1%
$2.49
-3.31%
-0.08Today
Boundless Bio last closing stock price
MetricPriceDate
Last closeUSD 2.572026-07-24
Boundless Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.63%USD 2.482026-07-17
1 month-1.15%USD 2.602026-06-24
3 month+71.33%USD 1.502026-04-24
Year to date+114.17%USD 1.202025-12-31
1 year+105.6%USD 1.252025-07-24
Since inception-81.96%USD 14.252024-03-28

Boundless Bio Financials at a Glance

Market Cap

$57.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$55.99M

EPS (TTM)

-$2.50

P/E Ratio

-1.03

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$2.49

Volume

121,469.22

Open

$2.57

Previous Close

$2.48

Daily Range

$2.46 - $2.60

52-Week Range

$0.96 - $2.79

Estimated Earnings Date

Aug 4, 2026

BOLD News

Foolcom-Featured.png

Boundless Bio (BOLD) Q2 R&D Drops 17%

Motley Fool Markets TeamAug 5, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Boundless Bio

Boundless Bio develops medicines for people with hard-to-treat cancers. Its main drugs aim to stop cancer growth by targeting unique DNA changes in tumor cells.

What’s in the Boundless Bio Toolbox?

BBI-355 (CHK1 inhibitor): Oral drug in early trials for cancers with extra copies of certain genes. 0% of revenue, as the company is pre-revenue.

BBI-825 (RNR inhibitor): Oral drug in early trials for cancers resistant to other treatments. 0% of revenue.

BBI-355/BBI-825 Combo: Combined use of both drugs, tested for stronger effect in specific cancers. 0% of revenue for Q2 2025.

BBI-940 (Kinesin inhibitor): Drug in preclinical stage, targets cell division in cancer with unique DNA. 0% of revenue for Q2 2025.

ECHO Diagnostic: Test to find patients with the right DNA changes for these drugs. 0% of revenue for Q2 2025.

Spyglass Platform: Technology to discover new drug targets in cancer cells with abnormal DNA. 0% of revenue for Q2 2025.

Growth Moves: Boundless Bio’s Playbook

Changed name from Pretzel Therapeutics to Boundless Bio in July 2019.

Initiated Phase 1/2 trials for BBI-355 and BBI-825.

Opened combination trial arm for BBI-355/BBI-825 in 2025.

Announced workforce reduction and program focus in May 2025.

Plans to submit BBI-940 for clinical testing in 2026.

Why Boundless Bio Stands Out (Without the Lab Coat)

Boundless Bio targets a cancer-specific DNA feature not found in healthy cells. Its technology platform finds new ways to attack tumors that resist standard drugs. The company keeps full control of its drug programs and uses its own test to match patients to treatments.

Five Things You Need to Know

Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.

Net loss was $16 million in Q2 2025, improving 7.7% from Q2 2024.

Cash and short-term investments totaled $127.1 million as of June 30, 2025.

Operating expenses were $17.1 million in Q2 2025.

Company expects current funds to last into the first half of 2028.

Bottom Line

Boundless Bio focuses on new cancer drug approaches for tough-to-treat tumors. The company remains pre-revenue, with early-stage programs and a strong cash position as of mid-2025.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Zachary D. Hornby, MBA

Website

www.boundlessbio.com

Headquarters

San Diego, CA 92121, US

BOLD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-53.60%

Return on Capital

-43.03%

Return on Assets

-39.72%

Earnings Yield

-97.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$57.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.47M

Volume

121.47K

Avg. Volume

1.26M

Financials (TTM)

Gross Profit

-$1.22M

Operating Income

-$60.69M

EBITDA

-$54.78M

Operating Cash Flow

-$47.10M

Capital Expenditure

-$495.00K

Free Cash Flow

-$47.60M

Cash & ST Invst.

$92.85M

Total Debt

$48.29M

Boundless Bio Performance Analysis

Boundless Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Boundless Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Boundless Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.0682.1%
20232023-12-31USD -2.227.7%
20242024-12-31USD -3.8573.1%
20252025-12-31USD -2.60-32.4%
Boundless Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301.4%
Q32025-09-3011.4%
Q42025-12-316.5%
Q12026-03-31-3.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$284.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$57.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.06M

N/A

Employees

28

N/A

Net Income

-$13.56M

+14.0%

EBITDA

-$13.27M

+14.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$92.85M

-32.8%

Total Debt

$48.29M

-0.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$45.00M

-6.8%

Short Term Debt

$3.28M

+1153.4%

Return on Assets

-39.72%

N/A

Return on Invested Capital

-46.19%

N/A

Free Cash Flow

-$14.98M

-2.7%

Operating Cash Flow

-$14.97M

-3.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLYBRallybio Corporation
$16.31+0.00%
NXTCNextCure, Inc.
$5.12+20.75%
PLURPluri Inc.
$1.64-7.87%
INTSIntensity Therapeutics, Inc.
$4.57+2.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About BOLD

What is the current price of Boundless Bio?

Boundless Bio is trading at $2.48 per share.

What is the 52-week range for Boundless Bio?

Over the past 52 weeks, Boundless Bio has traded between $0.96 and $2.79.

How much debt does Boundless Bio have?

As of the most recent reporting period, Boundless Bio reported total debt of $48.29M.

How much cash does Boundless Bio have on hand?

Boundless Bio reported $17.48M in cash and cash equivalents in its most recent financial results.

What is Boundless Bio’s dividend yield?

Boundless Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services